MediWound Reports Q3 2025 Financials and Corporate Update
Ticker: MDWD · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1593984
| Field | Detail |
|---|---|
| Company | Mediwound Ltd. (MDWD) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, corporate-update, 6-K
TL;DR
MediWound dropped its Q3 2025 earnings report and corporate update on Nov 20.
AI Summary
MediWound Ltd. reported its third quarter 2025 financial results and provided a corporate update on November 20, 2025. The company issued a press release detailing these results and updates, which is attached as Exhibit 99.1 to this Form 6-K filing.
Why It Matters
This filing provides investors with the latest financial performance and strategic developments for MediWound Ltd. during the third quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not contain significant new risk factors.
Key Players & Entities
- MediWound Ltd. (company) — Registrant
- November 20, 2025 (date) — Date of press release and filing
- Third Quarter 2025 (period) — Reporting period for financial results
- Exhibit 99.1 (document) — Attached press release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report MediWound Ltd.'s third quarter 2025 financial results and provide a corporate update, as detailed in a press release attached as Exhibit 99.1.
When was the press release announcing the Q3 2025 results issued?
The press release was issued on November 20, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 42 Hayarkon Street, Yavne, 8122745, Israel.
Does MediWound Ltd. file annual reports under Form 20-F or Form 40-F?
MediWound Ltd. files its annual reports under Form 20-F.
What is the SIC code for MediWound Ltd.?
The Standard Industrial Classification (SIC) code for MediWound Ltd. is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.
Filing Stats: 318 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-11-20 07:04:59
Filing Documents
- zk2534043.htm (6-K) — 9KB
- exhibit_99-1.htm (EX-99.1) — 404KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001178913-25-003917.txt ( ) — 418KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On November 20, 2025, MediWound Ltd. (the "Company") issued a press release entitled "MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update". A copy of this press release is attached to this Form 6-K as Exhibit 99.1. The contents of this Report of Foreign Private Issuer on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company) are hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 20, 2025 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated November 20, 2025 titled "MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update".